PMID- 26636767
OWN - NLM
STAT- MEDLINE
DCOM- 20160626
LR  - 20221207
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 12
DP  - 2015
TI  - Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET 
      Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients.
PG  - e0143468
LID - 10.1371/journal.pone.0143468 [doi]
LID - e0143468
AB  - To investigate the relationships between Chromosome 7 gain, 
      mesenchymal-epithelial transition factor (MET) gene copy number increase and MET 
      protein overexpression in Chinese patients with papillary renal cell carcinoma 
      (PRCC), immunohistochemistry (IHC), immunofluorescence (IF) and fluorescence in 
      situ hybridization (FISH) were performed on 98 formalin-fixed, paraffin-embedded 
      (FFPE) PRCC samples. Correlations between MET gene copy number increase, 
      Chromosome 7 gain and MET protein overexpression were analyzed statistically. A 
      highly significant correlation was observed between the percentage of tumor cells 
      with MET gene copy number >/=3 and CEP7 copy number >/=3 (R2 = 0.90, p<0.001) across 
      two subtypes of PRCC. In addition, the percentage of tumor cells with MET gene 
      copy number >/=3 was found to increase along with increases in MET IHC score. This 
      correlation was further confirmed in those PRCC tumor cells with average MET gene 
      copy number >5 using combined IF and FISH methodology. Overall, this study 
      provides evidence that Chromosome 7 gain drives MET gene copy number increase in 
      PRCC tumors, and appears to subsequently lead to an increase in MET protein 
      overexpression in these tumor cells. This supports MET activation as a potential 
      therapeutic target in sporadic PRCC.
FAU - Yin, Xiaolu
AU  - Yin X
AD  - Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
FAU - Zhang, Tianwei
AU  - Zhang T
AD  - Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
FAU - Su, Xinying
AU  - Su X
AD  - Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
FAU - Ji, Yan
AU  - Ji Y
AD  - Research & Development Information, AstraZeneca R&D, Shanghai, China.
FAU - Ye, Peng
AU  - Ye P
AD  - Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
FAU - Fu, Haihua
AU  - Fu H
AD  - Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
FAU - Fan, Shuqiong
AU  - Fan S
AD  - Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
FAU - Shen, Yanying
AU  - Shen Y
AD  - Department of Pathology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, China.
FAU - Gavine, Paul R
AU  - Gavine PR
AD  - Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
FAU - Gu, Yi
AU  - Gu Y
AD  - Asia & Emerging Markets iMed, AstraZeneca R&D, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151204
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - EC 2.7.10.1 (MET protein, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
MH  - Asian People/genetics
MH  - Carcinoma, Renal Cell/*genetics/metabolism/pathology
MH  - China
MH  - Chromosomes, Human, Pair 7/*genetics
MH  - Female
MH  - *Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Kidney Neoplasms/*genetics/*metabolism
MH  - Male
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-met/*genetics
MH  - Up-Regulation
PMC - PMC4670110
COIS- Competing Interests: Authors affiliated with AstraZeneca are full-time employees 
      and/or stakeholders of AstraZeneca. AstraZeneca sponsored this study. This does 
      not alter the authors' adherence to PLOS ONE policies on sharing data and 
      materials. The authors declare that they have no other competing interests.
EDAT- 2015/12/05 06:00
MHDA- 2016/06/28 06:00
PMCR- 2015/12/04
CRDT- 2015/12/05 06:00
PHST- 2015/06/29 00:00 [received]
PHST- 2015/11/05 00:00 [accepted]
PHST- 2015/12/05 06:00 [entrez]
PHST- 2015/12/05 06:00 [pubmed]
PHST- 2016/06/28 06:00 [medline]
PHST- 2015/12/04 00:00 [pmc-release]
AID - PONE-D-15-28499 [pii]
AID - 10.1371/journal.pone.0143468 [doi]
PST - epublish
SO  - PLoS One. 2015 Dec 4;10(12):e0143468. doi: 10.1371/journal.pone.0143468. 
      eCollection 2015.